The objective of present study was to develop solid self-microemulsifying drug delivery system (SMEDDS) for improving the delivery of a BCS class II antidiabetic agent pioglitazone HCL and evaluated by in-vitro, and in-vivo techniques. Screening of excipients was done by determining the equilibrium solubility of pioglitazone HCL in different oils, surfactants and cosurfactants, pioglitazone HCL showed highest solubility in coconut oil (oil), Tween 80 (surfactant), PEG 400 (Co-surfactant) and phase diagram was constructed to identify the selfmicroemulsification region. Liquid SMEDDS was prepared and was converted to S-SMEDDS by spray-drying of the liquid SMEDDS in a laboratory spray dryer using aerosil 200 as solid carrier. Solid state characterization of the solid SMEDDS was performed by SEM, DSC and Xray powder diffraction. The optimized system possessed a mean globule size of 201.2 nm, PDI 0.457 and Zeta potential -0.975 mV. The prepared S-SMEDDS was filled in hard gelatin capsule shell size "0" and in-vitro dissolution study were performed, from dissolution study it was concluded that S-SMEDDS form of showed complete and faster dissolution as compared to marketed formulation of pioglitazone HCL (piosys 15 tablet). In-vivo performance of S-SMEDDS was evaluated in Wistar rat using plasma glucose level was determined by oral glucose tolerance test. The test formulation (1:1 C) showed significant reduction in plasma glucose level, after oral administration. A one month stability studies were performed (40 0 C & 75% RH) showed no change in physical appearance and dissolution rate of the drug.
INTRODUCTION
Oral route is the easiest and most convenient route of drug administration, being non invasive and cost effective. But major problem encountered in oral formulations (as estimated more than 50 % of oral formulations are found to be poorly aqueous soluble), is low bioavailability, giving rise to further problems like, high inter and intra subject variability, lack of dose uniformity and finally leading to therapeutic failure. The challenging task is to increase the bioavailability of drugs. Number of technological strategies are investigated for improving bioavailability like solid dispersions, cyclodextrins, micronization etc. But Self-microemulsifying Drug Delivery System (SMEDDS) have gained exposure for their ability to increase solubility and bioavailability of poorly aqueous soluble drugs with reduction in dose and also drugs are protected from hostile environment in gut. (Goyal, U. et al, 2011) Self microemulsifying drug delivery system(SMEDDS) are defined as isotropic mixtures of natural or synthetic oils, solid or liquid surfactants, or alternatively, one or more hydrophilic solvents and co-solvents/surfactants that have a unique ability of forming fine oil-in-water (o/w) micro emulsions upon mild agitation followed by dilution in aqueous media, such as GI fluids. SMEDDS spread readily in the GI tract, and the digestive motility of the stomach and the intestine provide the agitation necessary for self-emulsification. (Shukla, J.et al, 2010) Pioglitazone HCl, a widely prescribed anti diabetic drug belongs to class IΙ under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. Its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. Chemically pioglitazone HCL is 5-(4-[2-(5-ethylpyridin-2-yl) ethoxy] benzyl) thiazolidine -2, 4-Dione. It is a thiazolidinedione derivative which is useful in the treatment of non-insulin dependent diabetes mellitus (NIDDM). Is a off-white crystalline powder, relatively insoluble in water. The pKa of drug is 5.19 and half-life: 3-7 hrs. 
Mechanism of action of pioglitazone HCl
Pioglitazone HCL is used for the treatment of diabetes mellitus type 2 either alone or in combination with sulfonylureas. Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues; increases the expense of insulin-dependent glucose; decreases withdrawal of glucose from the liver; reduces quantity of glucose, insulin and glycated hemoglobin in the bloodstream. Although not clinically significant, pioglitazone decreases the level of triglycerides and increases that of high-density lipoproteins (HDL) without changing low-density lipoproteins (LDL) and total cholesterol in patients with disorders of lipid metabolism. The objective of the present work was to formulate a self microemulsifying drug delivery system (SMEDDS) for pioglitazone HCL because pioglitazone HCL have poor aqueous solubility, Since there is a decrease in solubility with increase in pH and the half life being 3-5 hrs, so is incomplete absorption and eliminated quickly from the conventional tablets. Pioglitazone HCL being a non-polar drug and cannot effectively break down the lattice structure of water and hence its aqueous solubility is low. The oral delivery of such drugs is frequently associated with low bioavailability which leads to high intra and inter subject variability and a lack of dose proportionality. So, study proposed to formulate a lipid-based system of pioglitazone hydrochloride to enhance its dissolution rate to achieve optimum oral bioavailability by using novel SMEDDS systems.
MATERIALS AND METHODS

Materials
Pioglitazone HCL was obtained as gift sample from Mylan Ltd., Sinnar. Coconut oil, Tween 80, PEG 400, aerosil 200 was purchased from Thomas Baker, Mumbai. Other reagents were of analytical-reagent grade. Marketed formulations of pioglitazone HCl tablet (Piosys 15) were purchased from the local drug store in Nashik city after checking their manufacturing license number, batch number, production and expiry date.
Preparation of pioglitazone HCL liquid SMEDDS
Liquid SMEDDS of pioglitazone HCL was successfully developed by determining solubility of pioglitazone in various oils, surfactants and co-surfactants and by constructing pseudo ternary diagram to identify micro emulsion region from that satisfactory composition was selected to prepare liquid SMEDDS. 
Percentage drug content
Specific amount of S-SMEDDS theoretically equivalent to 15mg of drug weighed and dispersed in 100 ml of AR grade ethanol and sonicated for 10 min then concentration was determined by UV at 269 nm The percentage drug entrapment can be calculated by using following formula:
Theoretical drug content
Micromeritic properties of S-SMEDDS
1) Bulk density
2) Tapped density
3) Angle of repose
4) Carr"s Compressibility Index
5) Hausner ratio
Determination of Emulsification time
In order to determine the emulsification time (the time needed to reach the emulsified and homogeneous mixture, upon dilution), solid SMEDDS theoretically equivalent to 15mg of drug was added to 100 mL of water at 37ºC with gentle agitation using magnetic stirrer at 100 rpm. 
Factorial design
The aim of present work was to achieve optimized formulations determining the effects of some important factors and their interactions during the process preparation on SMEDDS physiochemical properties. Meanwhile the SMEDDS were being processed; the impact of different factors had been evaluated by making changes in their quantity. Finally, three of the most significant factors had been chosen as the independent variables. In the next step, for determining the low and high levels of each factor, some formulations were made. According to a 2 3 factorial design and considering these two variables, an experimental matrix was performed. 
Droplet size
This is a crucial factor in self-emulsification performance because it determines the rate and extent of drug release as well as the stability of the emulsion. Droplet size and distribution was determined by Malvern Zetasizer. About 1.0 gm sample was dissolved in double distilled water and agitated to get homogeneous dispersion. Mean globule diameter and distribution was determined (Bhagwat A. D. et al., 2012).
Zeta potential study
The micro particles were dispersed in distilled water. The S-SMEDDS were diluted with a ratio of 1:10000 (v/v) and mixed for 1min with cyclo mixer. This dispersion was filled in zeta cell and placed in the Zeta sizer and the zeta potentials were determined. ( 
Differential scanning calorimetry (DSC)
For this study, the powder sample (1 to 5 mg) was packed in an aluminum pan and crimped. The crimped pan was placed in the sample cell along with an empty pan as a reference. Temperature was increased to 300 0 C from 0 0 C at a rate of 10 0 C /min. (Yi Y. et al.2008 ).
X-ray powder diffractometry (XRD)
X-ray powder diffractometry method was used to investigate the effect of solubilisation of drug in SMEDDS and solidification by spray drying process on crystallinility of drug. The XRD patterns of drug powder and solid SEMDDS were recorded by using Panlytical Xpert Pro XRD at SAIF Punjab.
In-vitro drug release
The in-vitro drug release study was carried out as per IP 2014 and basket type dissolution apparatus (Electrolab, India) was used with some modifications. In 900 ml of 0.1 N HCL dissolution medium which was maintained at 37±0.5 0 C and rotated at 75 rpm, solid SMEDDS theoretically equivalent to 15 mg of drug were filled in size "0" hard gelatin capsule. Appropriate aliquots were withdrawn at suitable time interval (5, 10, 15, 20, 25, 30, 35, 45 min.) . After suitable dilutions aliquots were analyzed using UV spectrophotometer at 269 nm. Rats were dosed following an overnight fast for 16 hrs. 1 gm/kg glucose administered to each rat of glucose control group and blood samples were collected from rat tails and the glucose level was checked using blood glucose meter after 0, 30, 60, 120 min. Then glucose solution containing pure drug (1 gm of glucose+15 mg pioglitazone HCL) was administered to each of the rat orally of standard group The Plain drug suspension prepared by using 0.5% w/v CMC Na because pioglitazone HCL is virtually insoluble in water and glucose level were checked. The experiment was again repeated by administering samples containing glucose and optimized S-SMEDDS formulation in the same dose to test control. (Nipun T.S et al)
In vivo estimation of
Determination of Urine Sugar and ketones
Capillary tube method of urine collection was used to collect the urine sample from the diabetic rats (Hayashi and Sakaguchi, 1975). The rat was held with one hand and the lower part of the abdomen, around the urinary bladder, was pressed with the thumb and the third finger of the other hand of the collector, to cause urinary excretion. The urine excreted was immediately collected directly into two capillary tubes held between the index and middle fingers. After collection, Urinary blood glucose and ketone level was determined using by reagent based strips.
Only one drop of urine is kept on the test strips and the color change on the test strip was evaluated to determine the concentration of glucose by referring to the color index on test strip container [The Institutional Animal Care and Use Committee (IACUC) standard procedures.
(Sabina E. P et al, 2014)
Stability studies
The stability studies were carried out as per the ICH guidelines. The solid SMEDDS formulations were put into empty hard gelatin capsules (size 0) and subjected to stability studies. Stability study of the best formulation was carried out for one month at 40ºC and 75% RH. Samples were charged in stability chambers (Remi, Mumbai, India) with humidity and temperature control. After one month, the formulation was analyzed for appearance, drug content and in-vitro drug release. (Hyma P. et al, 2014)
RESULT AND DISCUSSION
Evaluation of prepared solid SMEDDS 3.1.1. Percentage practical yield
The yield of all S-SMEDDS batches was found from 45%-90.22%. Batch 2:1A showed highest yield 90.22%.
Percentage drug content
The content of drug in various S-SMEDDS formulation varies from 85.56 % to 98.10%. Batch 1:1C showed maximum drug content (98.10%). However, it was showed that as the surfactant increased in composition and oil decreased in composition of SMEDDS formulation, drug content was proportionally increased. All these results indicated that powder blend showed good flow properties. 
Micromeritic properties of S-SMEDDS
Determination of Emulsification time
Determination of Turbidity
It was observed that there is increase in turbidity with increase in amount of adsorbent. It was least for the formulation 1:1 C (154 NTU) where it is possible that the droplet size is least which decreased the turbidity. In interaction graph, inlet temperature and aspirator is evaluated by keeping release as a response, in which temp increases the release pattern linearly while Aspirator doesn"t show much significant impact on release.
Factorial design 3.1.6.1. Percentage Drug Release (% Drug release)
A. Analysis of Variance for Experimental matrix (ANOVA)
Figure 3. Contour plot of % Drug release
Counter plot was plotted to evaluate impact of Temperature and Aspirator on release of drug, and it was concluded that Increase in temperature and increase in Aspirator will lead to show gradual increase in release. From the graph it was observed that Yield was increased at lower temperature and higher Feed rate.
% Yield A. Analysis of Variance for Experimental Matrix (ANOVA) of % yield
Graph of Desirability Function
According to the final results, this program suggests some formulations and also predicted their responses containing a probability factor named "Desirability" that ranged between 0-1 that the most presumable answer would be the nearest to 1 and from graph optimized formulations are showing Desirability 1.
Figure 6. Graph for Desirability Function
From the graph it was observed that desirability value increases as Temperature increases and also increase in Feed rate. Desirability was observed 1at highest inlet temperature (75°C) and at high feed rate (4mL/min). The optimized solution obtained from the model was formulated and the results are performed in the triplicates for determination of % Drug release, % yield. The solution was found to complies all specifications hence considered optimized. Mean droplet size of reconstituted S-SMEDDS was found to be 201.2 nm with polydispersity index 0.457. S-SMEDDS showed polydispersity index less than 1, indicating uniform distribution of droplets throughout formulation.
Evaluation of optimized batch
Zeta potential study
Figure 8. Zeta potential of optimized S-SMEDDS formulation
zeta potential gives an indication of the potential stability of the colloidal system. If all the particles have a large negative or positive zeta potential they will repel each other and there is dispersion stability. Zeta potential of the system negative (−) mV, which indicates the droplets of microemulsion have negative charge. The zeta potential of optimized 1:1 C formulation was found to be −0.975and confirms the formulation of 1:1 C S-SMEDDS was stable. Figure 9 . SEM of optimized S-SMEDDS formulation SEM study showed that S-SMEDDS appeared as smooth surfaced S-SMEDDS particles, indicating that the liquid SMEDDS is adsorbed or coated inside the pores of Aerosil 200 with a lesser amount of aggregation. Figure 10 . DSC thermogram of Pioglitazone HCL Figure 11 . DSC thermogram of S-SMEDDS DSC curves of pioglitazone HCL shows sharp endothermic peak at near about 199.33°C. The S-SMEDDS exhibit retained small endothermic peak at 190.18°C for pioglitazone HCL and it may be due to solubilization of pioglitazone HCL in S-SMEDDS. Figure 12 . XRD pattern of pioglitazone HCL Figure 13 . XRD pattern of S-SMEDDS The X-ray powder diffraction pattern of pure drug shows crystallinities. S-SMEDDS revealed that the intensity of the peak for the pure drug was sharp, when it was incorporated into the self emulsifying system, then the peak intensities was decreased. It indicates that the crystalline nature of drug was changed to amorphous or must be present in molecularly dissolved state after formulation into S-SMEDDS.
Surface morphology by scanning electron microscopy (SEM)
Differential scanning calorimetry (DSC)
X-ray powder diffractometry (XRD)
In-vitro drug release
It was observed from the above results of in-vitro drug release study of all batches for 45 min, highest drug was released at 25 minute of dissolution in all batches. Also it was found that as the amount of adsorbent increases, drug release decreases. Increase in amount of Smix increases drug release to some extent. Maximum drug release was found in batch 1:1C. It may be due to amount of oil must be optimum for self emulsification. Also the proportion of oil with Smix sufficient to form droplets of smaller size so that maximum surface area available to get in contact with dissolution medium and hence maximum release. Also in vitro dissolution study of marketed tablet of pioglitazone HCL (Piosys 15) was studied with S-SMEDDS in HGF & 0.1 N HCL. So, from study it was found that drug release from S-SMEDDS is higher than marketed formulation and drug release rate depend on droplet size of emulsion. It could be suggested that the S-SMEDDS formulation resulted in spontaneous formation of a microemulsion with a small droplet size, which permitted a faster rate of drug release into the aqueous phase, much faster than that of marketed tablet. Thus, this greater availability of dissolved pioglitazone HCL from the S-SMEDDS formulation could lead to higher absorption and higher oral bioavailability. 
Determination of Urine Sugar and ketones
Reagent based strips showed no colour change. So, all groups showed absence of urine glucose and ketones. Figure 19 . Estimation of urine glucose and ketones
Stability studies
Generally, solid SMEDDS formulations are put into hard gelatin capsules as the final dosage form. The entire system has a very limited shelf life owing to its powder characteristics. Thus, the developed formulation was subjected to stability studies to evaluate its stability and the integrity of the dosage form. The results of the evaluation test conducted on stability samples. There was no significant change in the drug content, drug release (98.93%). It was also seen that the formulation was compatible with the hard gelatin capsule shells, as there was no sign of capsule shell deformation. There were also no significant changes in the appearance, or microemulsifying property. Thus, these studies confirmed the stability of the developed formulation. From the above tabulated results it can be concluded that there was no significant changes in the optimized batch of drug release & drug content.
CONCLUSION
Study concluded that S-SMEDDS of pioglitazone HCL could be developed using coconut oil, Tween 80 as surfactant, and PEG 400 as co surfactant in 1:1 ratio. The optimized formulation evaluated for drug content, DSC, SEM. This showed a minimum droplet size, zeta potential, good emulsification property and highest drug content also higher in-vitro drug release and better control of plasma glucose level in rats. From dissolution study it was concluded that S-SMEDDS formulation showed complete and faster drug release as compared to marketed tablet i.e., Piosys 15 tablet. Hence adsorption process using Aerosil 200 as solid carrier may efficiently formulate S-SMEDDS which enhance dissolution rate and concomitantly bioavailability. However stability studies indicates no significant degredation in developed S-SMEDDS and its compatibility with hard gelatin capsules. So study indicates that the potential use of S-SMEDDS for the oral delivery of pioglitazone HCL can be an alternative to improve its systemic availability.
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